Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

A study published by researchers from the Sant Pau Research Institute (IR Sant Pau) and the Stroke Unit of Sant Pau Hospital in the Journal of Lipid Research provides new evidence on the essential ...

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment ...

Findings of a new study suggest that the quality of LDL and HDL cholesterol, rather than their quantity, is more important in ...

But there was one number that made cardiologists raise their eyebrows – her elevated lipoprotein(a), usually written Lp(a), which is more than five times the level that puts someone at ...

Goldman Sachs initiated Silence Therapeutics (NASDAQ:SLN) with a Sell rating and a $6 price target on Tuesday, arguing that with only about $173M of cash and equivalents at the end of Q3 2024, the U.K ...

Fluctuating LDL and total cholesterol levels in older adults may indicate increased dementia and cognitive decline risk.

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

The core of the lipoprotein, containing cholesterol ester and TG, is nonpolar and hydrophobic, and the outer layer of the lipoprotein particle (containing free cholesterol, phospholipid ...

Variability in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) is associated with dementia and cognitive impairment.

High levels of variability in cholesterol over time were linked to a significantly higher risk for dementia and cognitive ...

Consultant cardiologist Chris Ellis looks at what we know and what we don’t know about lipoproteins, cardiovascular risk and ...